Alvotech, LOTTE Biologics Sign US Manufacturing Deal for Biosimilars
Alvotech and LOTTE Biologics have agreed to manufacture multiple biosimilar products at a New York facility, expanding global supply capacity.
Alvotech and LOTTE Biologics have entered into a manufacturing agreement to produce multiple biosimilar products at LOTTE Biologics' facility in Syracuse, New York, the companies announced. The collaboration is designed to strengthen global supply chains for biosimilar medicines, which are lower-cost alternatives to brand-name biologic drugs.
The Syracuse facility serves as the production hub under the agreement, positioning the partnership within the United States manufacturing base at a time when domestic pharmaceutical production has drawn heightened policy and investor attention. By anchoring output in New York, both companies aim to reduce supply-chain vulnerabilities that have affected the broader biologics sector.
Read more Ether.fi Integrates MoonPay Stack Into Self-Custodial Neobank →
Alvotech, an Iceland-headquartered biosimilar developer, and South Korea-based LOTTE Biologics bring complementary capabilities to the arrangement. Alvotech contributes its pipeline of biosimilar candidates, while LOTTE Biologics provides contract manufacturing infrastructure. The deal covers multiple products, though specific compounds and financial terms were not disclosed in the announcement.
The agreement reflects a broader industry trend of biosimilar developers securing dedicated manufacturing capacity ahead of anticipated market growth, as patents on major biologic therapies expire and payers push for lower-cost treatment options. Domestic US production agreements have become increasingly strategic as supply-chain resilience remains a priority across the pharmaceutical industry.
Continue reading at GlobeNewswire - Industry News on Financial Services.
